WO2008120070A2 - 2(hydroxyethyl)trimethylammonium thioctate (choline thioctate) displaying hepatoprotective, hypoammoniemic and detoxic action, a method for its production and a pharmaceutical composition based thereon - Google Patents
2(hydroxyethyl)trimethylammonium thioctate (choline thioctate) displaying hepatoprotective, hypoammoniemic and detoxic action, a method for its production and a pharmaceutical composition based thereon Download PDFInfo
- Publication number
- WO2008120070A2 WO2008120070A2 PCT/IB2008/000727 IB2008000727W WO2008120070A2 WO 2008120070 A2 WO2008120070 A2 WO 2008120070A2 IB 2008000727 W IB2008000727 W IB 2008000727W WO 2008120070 A2 WO2008120070 A2 WO 2008120070A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- thioctate
- choline
- hepatoprotective
- hydroxyethyl
- trimethylammonium
- Prior art date
Links
- 229960001231 choline Drugs 0.000 title claims abstract description 43
- 229940068511 thioctate Drugs 0.000 title claims abstract description 43
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 title claims abstract description 42
- 230000002443 hepatoprotective effect Effects 0.000 title claims abstract description 30
- 238000000034 method Methods 0.000 title claims abstract description 28
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 17
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 title claims abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 11
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 title abstract 8
- 230000009471 action Effects 0.000 title description 2
- 230000000694 effects Effects 0.000 claims abstract description 27
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims description 56
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 19
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 claims description 17
- 229960002663 thioctic acid Drugs 0.000 claims description 17
- 235000019136 lipoic acid Nutrition 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 239000002798 polar solvent Substances 0.000 claims description 5
- 150000007524 organic acids Chemical class 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 abstract description 26
- 239000003814 drug Substances 0.000 abstract description 25
- 229940079593 drug Drugs 0.000 abstract description 22
- 239000013543 active substance Substances 0.000 abstract description 11
- 239000002552 dosage form Substances 0.000 abstract description 5
- 238000001228 spectrum Methods 0.000 abstract description 5
- 238000004904 shortening Methods 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 22
- 239000000047 product Substances 0.000 description 16
- 210000004185 liver Anatomy 0.000 description 11
- 230000007170 pathology Effects 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 208000019423 liver disease Diseases 0.000 description 7
- RVEWUBJVAHOGKA-WOYAITHZSA-N Arginine glutamate Chemical compound OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CCCNC(N)=N RVEWUBJVAHOGKA-WOYAITHZSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 6
- 208000006454 hepatitis Diseases 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical group [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 229960002989 glutamic acid Drugs 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- -1 6-aminocapronic acid glutamate Chemical compound 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 3
- 235000009697 arginine Nutrition 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229960002104 cyanocobalamin Drugs 0.000 description 3
- 235000000639 cyanocobalamin Nutrition 0.000 description 3
- 239000011666 cyanocobalamin Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 239000003978 infusion fluid Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 235000019743 Choline chloride Nutrition 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 235000010841 Silybum marianum Nutrition 0.000 description 2
- 244000272459 Silybum marianum Species 0.000 description 2
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000004716 alpha keto acids Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229960003178 choline chloride Drugs 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000003495 polar organic solvent Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 2
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 2
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 2
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 2
- 239000012429 reaction media Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- SEBFKMXJBCUCAI-WAABAYLZSA-N (2r,3r)-3,5,7-trihydroxy-2-[(2s,3s)-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-dihydrochromen-4-one Chemical compound C1=C(O)C(OC)=CC([C@H]2[C@@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-WAABAYLZSA-N 0.000 description 1
- QWJSAWXRUVVRLH-LREBCSMRSA-M 2-hydroxyethyl(trimethyl)azanium;(2r,3r)-2,3,4-trihydroxy-4-oxobutanoate Chemical compound C[N+](C)(C)CCO.OC(=O)[C@H](O)[C@@H](O)C([O-])=O QWJSAWXRUVVRLH-LREBCSMRSA-M 0.000 description 1
- JXUHSUSCLWIKEW-UHFFFAOYSA-N 4-[(dimethylazaniumyl)methyl]-3-ethoxycarbonyl-2-phenyl-1-benzofuran-5-olate Chemical compound O1C2=CC=C(O)C(CN(C)C)=C2C(C(=O)OCC)=C1C1=CC=CC=C1 JXUHSUSCLWIKEW-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 208000017283 Bile Duct disease Diseases 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical class C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- IMAGLCGCHKGGLR-UHFFFAOYSA-M Choline orotate Chemical compound C[N+](C)(C)CCO.[O-]C(=O)C1=CC(=O)NC(=O)N1 IMAGLCGCHKGGLR-UHFFFAOYSA-M 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 239000009095 Hepatofalk Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- ULEBESPCVWBNIF-BYPYZUCNSA-N L-arginine amide Chemical class NC(=O)[C@@H](N)CCCNC(N)=N ULEBESPCVWBNIF-BYPYZUCNSA-N 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001567 anti-fibrinolytic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000027119 bilirubin metabolic disease Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 208000036796 hyperbilirubinemia Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000001024 intrahepatic cholestasis Diseases 0.000 description 1
- 230000007872 intrahepatic cholestasis Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 230000003212 lipotrophic effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- ZBOBHFDVBPNIDH-UHFFFAOYSA-N n'-methylethanimidamide;hydrochloride Chemical compound Cl.CNC(C)=N ZBOBHFDVBPNIDH-UHFFFAOYSA-N 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000005895 oxidative decarboxylation reaction Methods 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229950000628 silibinin Drugs 0.000 description 1
- 235000014899 silybin Nutrition 0.000 description 1
- GQTHJBOWLPZUOI-FJXQXJEOSA-M sodium D-pantothenate Chemical compound [Na+].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O GQTHJBOWLPZUOI-FJXQXJEOSA-M 0.000 description 1
- 229940068459 sodium pantothenate Drugs 0.000 description 1
- UUDFBRWLHZIIQX-UHFFFAOYSA-M sodium;5-(dithiolan-3-yl)pentanoate Chemical compound [Na+].[O-]C(=O)CCCCC1CCSS1 UUDFBRWLHZIIQX-UHFFFAOYSA-M 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000032895 transmembrane transport Effects 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
- C07D339/02—Five-membered rings
- C07D339/06—Five-membered rings having the hetero atoms in positions 1 and 3, e.g. cyclic dithiocarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
- C07D339/02—Five-membered rings
- C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
Definitions
- the invention relates generally to medicine and chemical and pharmaceutical industry, and more particularly to a new physiologically active substance 2(hydroxyethyl)trimethylammonium thioctate (choline thioctate) which displays hepatoprotective, hypoammoniemic and detoxic activity, to a method for its production and to pharmaceutical compositions based thereon.
- 2(hydroxyethyl)trimethylammonium thioctate choline thioctate
- hepatoprotectors include substances of both vegetable and synthetic origins which exert a differently directed effect on metabolic processes.
- a structural and pharmacological analog to choline thioctate is choline chloride - a choline derivative (2-oxyethyltrimethylammonium hydroxide), which is a lipotropic substance preventing severe liver diseases from occurring during its atheroma.
- Choline chloride is used in medicine included in hepatoprotective drugs to treat liver diseases. It is also included in combined feed for farm animals. Its disadvantages include an insufficiently high level and limited spectrum of specific activity.
- thioctic acid plays a substantial role in regulating metabolic processes in the liver. As a coenzyme, it takes part in carbohydrate or protein metabolism, and it is one of the important components of the antioxidant system of organism.
- Thioctic acid plays an important role in ⁇ -keto acid oxidative decarboxylation reactions including pyruvic acid transformation into acetyl-CoA which will enter the Krebs cycle. A complex oxidation process of thioctic acid results in the formation of 3 ATP molecules this increasing significantly a cell energy potential.
- Thioctic acid activates the oxidation processes of fatty acids in mitochondrions this, in addition provides the cell with energy, reducing the content of substrates therein for triglyceride synthesis and preventing thereby fatty (adipose) degeneration of the liver and hyperlipidemia from developing.
- liver diseases The main reasons for a wide use of thioctic acid to treat liver diseases are as follows:
- Nitrogen oxide synthesis inhibition by hepatocytes the prevention and reduction of disorders of the rheological properties and vascular disorders.
- the study conducted has shown the prospects of providing a complex physiologically active substance based on choline base and thioctic acid, a further use of which, in particular, as hepatoprotector, improves substantially a patient's quality of life.
- hepatoprotective drugs Legalon, Karsil, Siliborum in the form of tablets, capsules, pellets and others which contain as their active ingredients flavonoids extracted from seeds of variegated thistle. These drugs are used to treat acute hepatitis, hepatocirrhosis, in supporting therapy of chronic diseases of the liver. When using these drugs, undesirable side effects in the form of laxative action, allergic reactions of skin tissues are reported.
- hepatoprotective drug Essentialle contains natural "essential" phospholipids - diglyceride esters of cholinephosphoric acid and unsaturated fatty acids (linolic, linoleic, and others) along with vitamins (pyridoxine, cyanocobalamin, nicotinamide, pantothenic acid).
- Essentialle is used in the form of 5-mL and 10-mL ampoules which contain respectively 250 mg and 1000 mg of "essential" phospholipids, 2.5 mg and 5 mg of pyridoxine hydrochloride, 10 ⁇ g and 15 ⁇ g of cyanocobalamin, 25 mg and 100 mg of nicotinamide, 1.5 mg and 3 mg of sodium pantothenate, as well as in the form of capsules which contain 175 mg of "essential" phospholipids, 3 mg of thiamine, 3 mg of riboflavin, 3 mg of pyridoxine hydrochloride, 3 mg of cyanocobalamin, 15 mg of nicotinamide and 3.3 mg of alpha- tocopherol acetate.
- the drug is useful to treat chronic hepatitis, degeneration and cirrhosis of the liver, as well as to treat liver involvement associated with diabetes, alcoholism and others. Undesirable side effects in the form of dyspeptic disorders are reported.
- hepatoprotective drug which contains as its active ingredient 2-phenyl-3-carbetoxy-4-dimethylaminomethyl-5-oxibenzofuran hydrochloride (vinboron, phenicaberan) and helps to preserve the liver ravine structure.
- Hepabene in the form capsules, which is a combined drug and contains extracts from medicinal herbs including variegated thistle with at least 22 mg of silibinin per capsule (4).
- Hepabene in the form of infusion solution, which contains a 5% solution of amino acids, which are the most suitable for the organism including arginine (5).
- Zixorin which is used in the form of capsules to treat functional hyperbilirubinemia in patients with chronic diffuse diseases of the liver, to treat jaundice caused by enzymopathies and benign intrahepatic cholestasis (6).
- Drag Hepatofalk which contains choline orotate as its active ingredient. It is used to treat toxic liver disorders (including alcoholic and drug disorders), acute and chronic hepatitis of various ethiology and hepatocirrhosis as a supporting therapy (7).
- a drag Lipovitan which contains choline tartrate as its active ingredient and is used to treat toxic liver disorders (8).
- arginine amide derivatives Known in the art is a method for producing arginine amide derivatives, the method comprising: activating N-acylarginine or a salt thereof; the acylation thereby of amines of formula NH 2 R in an organic solvent medium at the presence of a base; and liberating the target product, wherein dimethyl formamidinium chloride is used as the activating agent (10).
- 6-aminocapronic acid glutamate a substance which displays antifibrinolytic, anti-inflammatory and antimicrobial activity
- the method comprising: dissolving glutamic acid and 6-aminocapronic acid in water; adding an activated charcoal to the resulting solution while stirring; filtering the resulting solution of 6-aminocapronic acid glutamate salt; cooling the filtrate for the purpose of further isolating a precipitate; and filtering, washing and drying the resulting crystalline precipitate - 6-aminocapronic acid glutamate salt.
- a target product yield is 86% (11).
- the most similar to a method in accordance with the present invention is the method for producing a water-soluble salt L-arginine L-glutamate, the method comprising: dissolving L-arginine base in water, adding L-glutamic acid, while stirring, to the resulting L-arginine base solution up to pH 6.6 to 6.8; filtering the resulting water solution of L-arginine L-glutamate; introducing the water solution of L-arginine L-glutamate in ethanol till precipitation (at a filtrate wate ⁇ ethanol ratio of 1:(9.76-10.24); filtering and washing the resulting precipitate of L-arginine L- glutamate; drying L-arginine L-glutamate under vacuum at temperature not higher than 60 0 C for 4 to 5 hours. (12)
- the disadvantages of the prototype method include the complexity and a long duration of the manufacturing process, necessity to comply with strict temperature and time conditions.
- an object of the present invention is to provide a new physiologically active substance choline thioctate which, displaying hepatoprotective, hypoammoniemic and detoxic activity, possesses a higher level and a wider spectrum of specific activity.
- Another object of the present invention is to provide a method for producing a new chemical substance displaying hepatoprotective, hypoammoniemic and detoxic activity, which method, thanks to the sequence of process steps, the selection of process conditions and parameters, enables a substance with a higher level and a wider spectrum of specific activity to be produced while simplifying, and shortening the duration of, the manufacturing process.
- Yet another object of the present invention is to provide pharmaceutical compositions based on a new physiologically active substance choline thioctate in various dosage forms.
- the assigned object is achieved by that, in accordance with the present invention, 2(hydroxyethyl)trimethylammonium thioctate (choline thioctate) of formula
- the assigned object is achieved by that, in accordance with the present invention, in a method for producing 2(hydroxyethyl)trimethylammonium thioctate (choline thioctate), the method comprises: dissolving a base and an organic acid in polar solvents and further isolating the target product, choline base is used as the base, thioctic acid is used as the organic acid, water and/or ethanol is/are used as the polar solvent(s), and the target product is isolated by removing the solvent by any method known to those skilled in the art.
- the method comprises: dissolving a base and an organic acid in polar solvents and further isolating the target product, choline base is used as the base, thioctic acid is used as the organic acid, water and/or ethanol is/are used as the polar solvent(s), and the target product is isolated by removing the solvent by any method known to those skilled in the art.
- a pharmaceutical composition containing an active ingredient and one or more pharmaceutically suitable carriers or solvents contains as the active ingredient 2(hydroxyethyl)trimethylammonium thioctate (choline thioctate) of formula
- the technical result of implementing the present invention is the provision of a new physiologically active chemical substance 2(hydroxyethyl)trimethylammonium thioctate (choline thioctate) which displays hepatoprotective, hypoammoniemic and detoxic activity, the development of a method for producing the same which method ensures a higher level and a wider spectrum of specific activity while simplifying, and shortening the duration of the manufacturing process, as well as the provision of pharmaceutical compositions based on a new physiologically active substance 2(hydroxyemyl)trimethylammonium thioctate (choline thioctate) in various dosage forms the use whereof results in diversifying the range of hepatoprotective drugs.
- Example 1 To a mixture of 0.8497 g (0.004125 moles) of thioctic acid (calculated with reference to the substance of 100%) in ethanol add 0.5 g (0.004125 moles) of choline base (calculated with reference to the dried substance of 100%) and stir till a clear solution. To produce the target product (choline thioctate), distillate ethanol out of the solution and dry the resulting precipitate under vacuum.
- Example 2 To a suspension of 0.8497 g (0.004125 moles) of thioctic acid (calculated with reference to the substance of 100%) in water add 0.5 g (0.004125 moles) of choline base (calculated with reference to the substance of 100%) and stir till a clear solution. To produce the target product (choline thioctate), freeze- drying the solution.
- Example 3 Proceed as in Example 2. To produce the target product (choline thioctate), dry the solution by spray drying.
- Example 4 To a mixture of 0.5722 g (0.004125 moles) of choline hydrochloride (calculated with reference to the substance of 100%) in ethanol add 0.165 g (0.004125 moles) of sodium hydroxide (calculated with reference to the substance of 100%). Filter a sodium chloride precipitate, add 0.8497 g (0.004125 moles) of thioctic acid (calculated with reference to the substance of 100%) to the filtrate and stir till a clear solution. To produce the target product (choline thioctate), distillate ethanol out of the solution and dry the resulting precipitate under vacuum.
- Example 5 To a mixture of 0.8497 g (0.004125 moles) of thioctic acid (calculated with reference to the substance of 100%) in ethanol, add 0.165 g (0.004125 moles) of sodium hydroxide (calculated with reference to the substance of 100%) and mix. To the resulting solution of sodium thioctate, add 0.5722 g (0.004125 moles) of choline hydrochloride (calculated with reference to the substance of 100%). Filter a sodium chloride precipitate. To produce the target product (choline thioctate), distillate ethanol out of the solution and dry the resulting precipitate under vacuum.
- Example 6 Proceed as in Example 2 at a thioctic acid / choline base molar ratio of 1:1 to 1.2). To the resulting water solution of the target product, add pharmaceutically suitable adjuvants to produce an injection solution by any method known to those skilled in the art.
- Example 7 To pharmaceutically suitable adjuvants, add, while stirring, a concentrated water solution of choline thioctate produced in accordance with Example 2, then granulate, then granulate, dry and tablet or capsulate by any method known to those skilled in the art.
- a new physiologically active substance 2(hydroxyethyl)trimethylammonium thioctate (choline thioctate) is produced, which substance displays hepatoprotective, hypoammoniemic and detoxic activity.
- the selection of conditions and parameters ensure the attainment of the object of the present invention.
- the salt-forming reaction in producing choline thioctate occurs the most effectively in both polar solvents because of their specific properties (they perform a solvent function and a reaction medium function concurrently) and reagents - choline base and thioctic acid. It is to be understood that the present invention is not limited by selected ratios of solvents and choline base.
- the methods to produce choline thioctate by the prototype method failed to produce the target product because of that the output substance dissolves not only in water but also in ethanol, which is used as a salt-forming agent in producing L- arginine L-glutamate.
- the easiness of performing the salt-forming reaction, as well as its output reagents of a sufficient purity level which are used in an equivalent quantity ensure a high level of purity and stability of not only the target product but also pharmaceutical compositions when these solutions are used (a step of isolating the target product in a dry form is excluded thereby the manufacturing cycle is simplified significantly).
- the temperature conditions of salt-forming do not influence on product purity and are only limited the freezing point and boiling point of solvents which are used as a reaction medium. Only the pre-determined parameters of target product concentration determine a solvent quantity for salt-forming.
- choline thioctate based pharmaceutical compositions are produced in the form of tablets, capsules, powders, injection solutions, infusion solution concentrates, and other dosage forms.
- An active substance was selected by means of the pharmacological screening of a number of complex compounds produced and of a comparative pharmacological assessment with respect to Glutarginum (injection dosage form). Preliminary screening studies of pharmacological activity of the complexes were conducted for the existence of their hepatoprotective action.
- compositions Nos. 1 to 5 which contain, in 1 niL:
- Composition No. 1 10.0 mg of choline base + 17.0 mg of ⁇ -lipoic (thioctic) acid with 0.4 % of sodium chloride;
- Composition No. 2 14.4 mg of arginine base + 17.0 mg of ⁇ -lipoic (thioctic) acid; Composition No. 3: 10.0 mg of choline base + 17.0 mg of ⁇ -lipoic (thioctic) acid; Composition No. 4: 9.98 mg of choline base + 10.16 mg of nicotinic acid; Composition No.
- composition No. 3 The administration of test specimens to rats revealed their marked hepatoprotective activity. The highest (100%) effect was observed when composition No. 3 was administered.
- Composition No. 1 that, in addition to choline and lipoic acid, contained a 0.4 % solution of sodium chloride, exhibited a slightly lower activity (83.3%). The rest of the test compositions and Glutarginum were second to them in specific activity level.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to medicine and chemical and pharmaceutical industry, and more particularly to a new physiologically active substance 2(hydroxyethyl)trimethylammonium thioctate (choline thioctate) displaying hepatoprotective, hypoammoniemic and detoxic activity, to a method for producing said substance, and to pharmaceutical compositions based thereon. The technical result of implementing the invention is a new physiologically active chemical substance 2(hydroxyethyl)trimethylammonium thioctate (choline thioctate) displaying hepatoprotective, hypoammoniemic and detoxic activity, a method for producing the same which method ensures a higher level and a wider spectrum of specific activity while simplifying, and shortening the duration of the manufacturing process, and pharmaceutical compositions based on the new physiologically active substance 2(hydroxyethyl)trimethylammonium thioctate (choline thioctate) in various dosage forms the use whereof results in a diversified range of hepatoprotective drugs.
Description
2(HYDROXYETHYL)TRIMETHYLAMMONIUM THIOCTATE (CHOLINE
THIOCTATE) DISPLAYING HEPATOPROTECTIVE, HYPOAMMONIEMIC
AND DETOXIC ACTION, A METHOD FOR ITS PRODUCTION AND A
PHARMACEUTICAL COMPOSITION BASED THEREON
The invention relates generally to medicine and chemical and pharmaceutical industry, and more particularly to a new physiologically active substance 2(hydroxyethyl)trimethylammonium thioctate (choline thioctate) which displays hepatoprotective, hypoammoniemic and detoxic activity, to a method for its production and to pharmaceutical compositions based thereon.
The substance of the following structural formula
is a salt of choline base and thioctic acid solvable in water and some polar organic solvents and displays hepatoprotective, hypoammoniemic and detoxic activity.
Regarding hepatology, up to now, there has been remained significant the role of drugs which are used to treat liver and bile duct diseases and of those that protect the liver from a damaging influence of both exogenous and endogenous factors and/or accelerate its natural regeneration (hepatoprotectors). The group of hepatoprotectors includes substances of both vegetable and synthetic origins which exert a differently directed effect on metabolic processes.
The range of domestic drugs which display hepatoprotective, hypoammoniemic and detoxic activities is insufficient and, accordingly, what is relevant is the search for
new physiologically active substances which possess such specific activity and the provision, based thereon, of new high-efficacy drugs.
A structural and pharmacological analog to choline thioctate is choline chloride - a choline derivative (2-oxyethyltrimethylammonium hydroxide), which is a lipotropic substance preventing severe liver diseases from occurring during its atheroma. Choline chloride is used in medicine included in hepatoprotective drugs to treat liver diseases. It is also included in combined feed for farm animals. Its disadvantages include an insufficiently high level and limited spectrum of specific activity.
At present, drugs of thioctic (α-lipoic) acid (for instance, Thioctacid) attract close attention to the treatment of liver metabolic diseases. It is well known that thioctic acid plays a substantial role in regulating metabolic processes in the liver. As a coenzyme, it takes part in carbohydrate or protein metabolism, and it is one of the important components of the antioxidant system of organism. Thioctic acid plays an important role in α-keto acid oxidative decarboxylation reactions including pyruvic acid transformation into acetyl-CoA which will enter the Krebs cycle. A complex oxidation process of thioctic acid results in the formation of 3 ATP molecules this increasing significantly a cell energy potential. Thioctic acid activates the oxidation processes of fatty acids in mitochondrions this, in addition provides the cell with energy, reducing the content of substrates therein for triglyceride synthesis and preventing thereby fatty (adipose) degeneration of the liver and hyperlipidemia from developing.
The main reasons for a wide use of thioctic acid to treat liver diseases are as follows:
• Ability of reducing lipid peroxidation (binding free radicals and free tissue iron);
• Participation in fatty acid and acetate oxidation (it prevents fatty steatosis of the liver from developing);
• Participation in α-keto acid decarboxylation (the provision of cell with energy and ketoacidosis development prevention);
• Increase in glucose transmembrane transport to the cell (glycogen accumulation and increase in the energy balance of hepatocytes);
• Nitrogen oxide synthesis inhibition by hepatocytes (the prevention and reduction of disorders of the rheological properties and vascular disorders).
The study conducted has shown the prospects of providing a complex physiologically active substance based on choline base and thioctic acid, a further use of which, in particular, as hepatoprotector, improves substantially a patient's quality of life.
Known in the art are hepatoprotective drugs Legalon, Karsil, Siliborum in the form of tablets, capsules, pellets and others which contain as their active ingredients flavonoids extracted from seeds of variegated thistle. These drugs are used to treat acute hepatitis, hepatocirrhosis, in supporting therapy of chronic diseases of the liver. When using these drugs, undesirable side effects in the form of laxative action, allergic reactions of skin tissues are reported. (1)
A known in the art hepatoprotective drug Essentialle contains natural "essential" phospholipids - diglyceride esters of cholinephosphoric acid and unsaturated fatty acids (linolic, linoleic, and others) along with vitamins (pyridoxine, cyanocobalamin, nicotinamide, pantothenic acid). Essentialle is used in the form of 5-mL and 10-mL ampoules which contain respectively 250 mg and 1000 mg of "essential" phospholipids, 2.5 mg and 5 mg of pyridoxine hydrochloride, 10 μg and 15 μg of cyanocobalamin, 25 mg and 100 mg of nicotinamide, 1.5 mg and 3 mg of sodium pantothenate, as well as in the form of capsules which contain 175 mg of "essential" phospholipids, 3 mg of thiamine, 3 mg of riboflavin, 3 mg of pyridoxine hydrochloride, 3 mg of cyanocobalamin, 15 mg of nicotinamide and 3.3 mg of alpha- tocopherol acetate. The drug is useful to treat chronic hepatitis, degeneration and cirrhosis of the liver, as well as to treat liver involvement associated with diabetes, alcoholism and others. Undesirable side effects in the form of dyspeptic disorders are reported. (2)
Known in the art is a hepatoprotective drug, which contains as its active ingredient 2-phenyl-3-carbetoxy-4-dimethylaminomethyl-5-oxibenzofuran
hydrochloride (vinboron, phenicaberan) and helps to preserve the liver ravine structure. (3)
Known in the art is a hepatoprotective drug Hepabene in the form capsules, which is a combined drug and contains extracts from medicinal herbs including variegated thistle with at least 22 mg of silibinin per capsule (4).
Known in the art is a hepatoprotective drug Hepabene in the form of infusion solution, which contains a 5% solution of amino acids, which are the most suitable for the organism including arginine (5).
Known in the art is a drug Zixorin, which is used in the form of capsules to treat functional hyperbilirubinemia in patients with chronic diffuse diseases of the liver, to treat jaundice caused by enzymopathies and benign intrahepatic cholestasis (6).
Known in the art is a drag Hepatofalk, which contains choline orotate as its active ingredient. It is used to treat toxic liver disorders (including alcoholic and drug disorders), acute and chronic hepatitis of various ethiology and hepatocirrhosis as a supporting therapy (7).
Known in the art is a drag Lipovitan which contains choline tartrate as its active ingredient and is used to treat toxic liver disorders (8).
Known in the art is a drag Glutarginum (L-arginine L-glutamate) which displays hepatoprotective, hypoammoniemic and detoxic activity and is used in the form of tablets, capsules, powders, injection solutions and infusion solution concentrates (9).
Known in the art is a method for producing arginine amide derivatives, the method comprising: activating N-acylarginine or a salt thereof; the acylation thereby of amines of formula NH2R in an organic solvent medium at the presence of a base; and liberating the target product, wherein dimethyl formamidinium chloride is used as the activating agent (10).
Known in the art is a method for producing 6-aminocapronic acid glutamate, a substance which displays antifibrinolytic, anti-inflammatory and antimicrobial activity, the method comprising: dissolving glutamic acid and 6-aminocapronic acid in water; adding an activated charcoal to the resulting solution while stirring; filtering the resulting solution of 6-aminocapronic acid glutamate salt; cooling the filtrate for
the purpose of further isolating a precipitate; and filtering, washing and drying the resulting crystalline precipitate - 6-aminocapronic acid glutamate salt. A target product yield is 86% (11).
The most similar to a method in accordance with the present invention is the method for producing a water-soluble salt L-arginine L-glutamate, the method comprising: dissolving L-arginine base in water, adding L-glutamic acid, while stirring, to the resulting L-arginine base solution up to pH 6.6 to 6.8; filtering the resulting water solution of L-arginine L-glutamate; introducing the water solution of L-arginine L-glutamate in ethanol till precipitation (at a filtrate wateπethanol ratio of 1:(9.76-10.24); filtering and washing the resulting precipitate of L-arginine L- glutamate; drying L-arginine L-glutamate under vacuum at temperature not higher than 600C for 4 to 5 hours. (12)
The disadvantages of the prototype method include the complexity and a long duration of the manufacturing process, necessity to comply with strict temperature and time conditions.
Accordingly, an object of the present invention is to provide a new physiologically active substance choline thioctate which, displaying hepatoprotective, hypoammoniemic and detoxic activity, possesses a higher level and a wider spectrum of specific activity.
Another object of the present invention is to provide a method for producing a new chemical substance displaying hepatoprotective, hypoammoniemic and detoxic activity, which method, thanks to the sequence of process steps, the selection of process conditions and parameters, enables a substance with a higher level and a wider spectrum of specific activity to be produced while simplifying, and shortening the duration of, the manufacturing process.
Yet another object of the present invention is to provide pharmaceutical compositions based on a new physiologically active substance choline thioctate in various dosage forms.
The assigned object is achieved by that, in accordance with the present invention, 2(hydroxyethyl)trimethylammonium thioctate (choline thioctate) of formula
The assigned object is achieved by that, in accordance with the present invention, in a method for producing 2(hydroxyethyl)trimethylammonium thioctate (choline thioctate), the method comprises: dissolving a base and an organic acid in polar solvents and further isolating the target product, choline base is used as the base, thioctic acid is used as the organic acid, water and/or ethanol is/are used as the polar solvent(s), and the target product is isolated by removing the solvent by any method known to those skilled in the art.
The assigned object is achieved by that, in accordance with the present invention, a pharmaceutical composition containing an active ingredient and one or more pharmaceutically suitable carriers or solvents contains as the active ingredient 2(hydroxyethyl)trimethylammonium thioctate (choline thioctate) of formula
which displays hepatoprotective, hypoammoniemic and detoxic activity.
The technical result of implementing the present invention is the provision of a new physiologically active chemical substance 2(hydroxyethyl)trimethylammonium thioctate (choline thioctate) which displays hepatoprotective, hypoammoniemic and detoxic activity, the development of a method for producing the same which method ensures a higher level and a wider spectrum of specific activity while simplifying, and shortening the duration of the manufacturing process, as well as the provision of
pharmaceutical compositions based on a new physiologically active substance 2(hydroxyemyl)trimethylammonium thioctate (choline thioctate) in various dosage forms the use whereof results in diversifying the range of hepatoprotective drugs.
Particular examples of preferred embodiments of the invention are the following:
Example 1: To a mixture of 0.8497 g (0.004125 moles) of thioctic acid (calculated with reference to the substance of 100%) in ethanol add 0.5 g (0.004125 moles) of choline base (calculated with reference to the dried substance of 100%) and stir till a clear solution. To produce the target product (choline thioctate), distillate ethanol out of the solution and dry the resulting precipitate under vacuum.
Example 2: To a suspension of 0.8497 g (0.004125 moles) of thioctic acid (calculated with reference to the substance of 100%) in water add 0.5 g (0.004125 moles) of choline base (calculated with reference to the substance of 100%) and stir till a clear solution. To produce the target product (choline thioctate), freeze- drying the solution.
Example 3: Proceed as in Example 2. To produce the target product (choline thioctate), dry the solution by spray drying.
Example 4: To a mixture of 0.5722 g (0.004125 moles) of choline hydrochloride (calculated with reference to the substance of 100%) in ethanol add 0.165 g (0.004125 moles) of sodium hydroxide (calculated with reference to the substance of 100%). Filter a sodium chloride precipitate, add 0.8497 g (0.004125 moles) of thioctic acid (calculated with reference to the substance of 100%) to the filtrate and stir till a clear solution. To produce the target product (choline thioctate), distillate ethanol out of the solution and dry the resulting precipitate under vacuum.
Example 5: To a mixture of 0.8497 g (0.004125 moles) of thioctic acid (calculated with reference to the substance of 100%) in ethanol, add 0.165 g (0.004125 moles) of sodium hydroxide (calculated with reference to the substance of 100%) and mix. To the resulting solution of sodium thioctate, add 0.5722 g (0.004125 moles) of choline hydrochloride (calculated with reference to the substance of 100%). Filter a sodium chloride precipitate. To produce the target product (choline thioctate), distillate ethanol out of the solution and dry the resulting precipitate under vacuum.
Example 6: Proceed as in Example 2 at a thioctic acid / choline base molar ratio of 1:1 to 1.2). To the resulting water solution of the target product, add pharmaceutically suitable adjuvants to produce an injection solution by any method known to those skilled in the art.
Example 7: To pharmaceutically suitable adjuvants, add, while stirring, a concentrated water solution of choline thioctate produced in accordance with Example 2, then granulate, then granulate, dry and tablet or capsulate by any method known to those skilled in the art.
In the event that a manufacturer has problems in purchasing the substance choline base, it may be produced in accordance with Examples 4 and 5.
By the method in accordance with the present invention, a new physiologically active substance 2(hydroxyethyl)trimethylammonium thioctate (choline thioctate) is produced, which substance displays hepatoprotective, hypoammoniemic and detoxic activity. This is an amorphous, yellowish-colored product (a yield of about 100%) of high purity (a content of main substance is not less than 98.5%), soluble in water and polar organic solvents: C13 H27 NO3S2 (molecular weight =309.53)
Elemental Analysis Results
Both interrelation and sequence of the steps of of the method in accordance with the present invention, the selection of conditions and parameters ensure the attainment of the object of the present invention. Thus, the salt-forming reaction in producing choline thioctate occurs the most effectively in both polar solvents because of their specific properties (they perform a solvent function and a reaction medium function concurrently) and reagents - choline base and thioctic acid. It is to be understood that the present invention is not limited by selected ratios of solvents and choline base.
Table 1
Comparative Analysis the Method in Accordance with the Present Invention and the
Prototype Method
The methods to produce choline thioctate by the prototype method failed to produce the target product because of that the output substance dissolves not only in water but also in ethanol, which is used as a salt-forming agent in producing L- arginine L-glutamate. The easiness of performing the salt-forming reaction, as well as its output reagents of a sufficient purity level which are used in an equivalent quantity, ensure a high level of purity and stability of not only the target product but also pharmaceutical compositions when these solutions are used (a step of isolating the
target product in a dry form is excluded thereby the manufacturing cycle is simplified significantly). In the method in accordance with the present invention, the temperature conditions of salt-forming do not influence on product purity and are only limited the freezing point and boiling point of solvents which are used as a reaction medium. Only the pre-determined parameters of target product concentration determine a solvent quantity for salt-forming.
In accordance with the present invention, choline thioctate based pharmaceutical compositions are produced in the form of tablets, capsules, powders, injection solutions, infusion solution concentrates, and other dosage forms.
An active substance was selected by means of the pharmacological screening of a number of complex compounds produced and of a comparative pharmacological assessment with respect to Glutarginum (injection dosage form). Preliminary screening studies of pharmacological activity of the complexes were conducted for the existence of their hepatoprotective action.
At the first stage of these studies, the most active compound was revealed based whereon further comparative studies were performed.
In the hepatitis model in rats, which hepatitis was induced by intragastric administration of carbon tetrachloride, there was conducted a comparative study of hepatoprotective activity of those complexes (compositions Nos. 1 to 5) which contain, in 1 niL:
Composition No. 1 : 10.0 mg of choline base + 17.0 mg of α-lipoic (thioctic) acid with 0.4 % of sodium chloride;
Composition No. 2: 14.4 mg of arginine base + 17.0 mg of α-lipoic (thioctic) acid; Composition No. 3: 10.0 mg of choline base + 17.0 mg of α-lipoic (thioctic) acid; Composition No. 4: 9.98 mg of choline base + 10.16 mg of nicotinic acid; Composition No. 5: 9.98 mg of choline base + 12.1 mg of glutamic acid; Drug Berlition commercially available from Berlin-Chemie AG: 133 mg of lipoic (thioctic) acid / 12 mL;
Drug Glutarginum for Injection commercially available from Pharmaceutical Company Zdorovye Ltd.: 200 mg / 5 mL (22 mg of arginine + 18 mg of glutamic acid in 1 mL).
The experimental studies were conducted on 48 outbred white rats, both male and female, of 230 to 260 g of body weight. Carbon tetrachloride was administered to the animals in the form of a 50% oil emulsion intragastrically, once, at a dose of 0.8 mL/100 g b.w. Tested drag specimens were administered intravenously into the caudal vein for three days prior to the administration of a toxic agent, as well as for three days following the administration of the toxic agent (to the animals survived. The tested drug specimens were administered to the animals at the following doses:
In this study, the animals were divided into 8 groups of 6 rats in each:
1 - Pathology control;
2 - Pathology + Composition No. 1 at a dose of 0.5 mg/kg;
3 - Pathology + Composition No. 2 at a dose of 0.5 mg/kg;
4 - Pathology + Composition No. 3 at a dose of 0.5 mg/kg;
5 - Pathology + Composition No. 4 at a dose of 0.5 mg/kg;
6 - Pathology + Composition No. 5 at a dose of 0.5 mg/kg;
7 - Pathology + Berlition at a dose of 0.34 mg/kg;
8 - Pathology + Glutarginum at a dose of 0.35 mg/kg.
The selection of doses was based on the fact that the animals should receive substances at the same doses close to the doses recommended in clinics for humans.
As a result of the experimental study, it was found that 5 of 6 rats in the pathology control group died on Day 3 to Day 5 after dosing (Table 2) this corresponds to the data, which are known from literature and to our own studies which are the evidence of the development of acute hepatic pathology in rats and death of as a rule 60% to 80% of rats.
Table 2
The administration of test specimens to rats revealed their marked hepatoprotective activity. The highest (100%) effect was observed when composition No. 3 was administered. Composition No. 1 that, in addition to choline and lipoic acid, contained a 0.4 % solution of sodium chloride, exhibited a slightly lower activity (83.3%). The rest of the test compositions and Glutarginum were second to them in specific activity level.
At the same time, the dose of Glutarginum was nearly 3 times higher than the dose of the most active test compound.
As a result of these preliminary experiments, it was found that the most active complex displayed a 100% hepatoprotective activity. In theses experiments, Glutarginum exhibited a 67% effect.
It may be, thus, concluded that the physiologically active substance choline thioctate displays a marked hepatoprotective activity, which exceeds that of Glutarginum, which was used at a higher dose. The complex in accordance with the present invention is promising for producing, based thereon, monodrugs or complex drugs of hepatoprotective activity.
Under Power of Attorney V. Mikhailyuk, Patent Attorney
REFERENCES:
1. M. D. Mashkovskiy, Drugs, Torsing, Kharkov (1997), Vol. 1 - 514-516.
2. M. D. Mashkovskiy, Drugs, Torsing, Kharkov (1997), Vol. 1 - 514.
3. The Russian Federation Patent No. 2,211,034, IPC A61K 31/3343, A61P 1/16. Official Bulletin of Rospatent "Inventions, Utility Models" of 27.08.2003.
4. Vidal, Drugs in Russia - Reference Book, Moscow, AstraPharmService (2001) B-132.
5. Vidal, Drugs in Russia - Reference Book, Moscow, AstraPharmService (2001) B-472.
6. M. D. Mashkovskiy, Drugs, Torsing, Kharkov (1997), Vol. 1 - 516.
7. ROTE LISTE 2000, No. 48053.
8. ROTE LISTE 2000, No. 48056.
9. Ukrainian Patent No. 54,880, Cl. C07C229/02, A61K31/195, A61P1/16, A61P39/00, O racial Bulletin "Industrial Property" (2003), No.3, page 2
10. USSR Inventor's Certificate No. 1,266,139. Cl. C07 C 103/187, published on July 03, 19S4.
11. USSR Inventor's Certificate No. 1,248,212. Cl. C 07 C 101/22, A 61 K 31/195, published on July 27, 1983.
12. Ukrainian Patent No. 54,880, Cl. C07C229/02, A61K31/195, A61P1/16, A61P39/00, Official Bulletin "Industrial Property" (2003), No.3, page 3.
Claims
1. 2(hydroxyethyl)trimemylammonium thioctate (choline thioctate) of formula
2. A method for producing 2(hydroxyethyl)trimethylammonium thioctate (choline thioctate), the method comprising: dissolving a base and an organic acid in polar solvents and further isolating the target product, characterized in that choline base is used as the base, thioctic acid is used as the organic acid, water and/or ethanol is/are used as the polar solvent(s), and the target product is isolated by removing the solvent by any method known to those skilled in the art.
3. A pharmaceutical composition containing an active ingredient and one or more pharmaceutically suitable carriers or solvents, characterized in that said composition contains as the active ingredient 2(hydroxyethyl)trimethylammonium thioctate (choline thioctate) of formula
which displays hepatoprotective, hypoammoniemic and detoxic activity.
Under Power of Attorney V. Mikhailyuk, Patent Attorney
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAA200703481 | 2007-03-30 | ||
| UAA200703481A UA86441C2 (en) | 2007-03-30 | 2007-03-30 | (2-hydroxyethyl)trimethylammonium thiooctate (choline thioctate), having hepatoprotective, hypoamoniemic and detoxic action, method for production thereof and pharmaceutical compositions based on it |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2008120070A2 true WO2008120070A2 (en) | 2008-10-09 |
| WO2008120070A3 WO2008120070A3 (en) | 2008-12-31 |
Family
ID=39808755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2008/000727 WO2008120070A2 (en) | 2007-03-30 | 2008-03-17 | 2(hydroxyethyl)trimethylammonium thioctate (choline thioctate) displaying hepatoprotective, hypoammoniemic and detoxic action, a method for its production and a pharmaceutical composition based thereon |
Country Status (2)
| Country | Link |
|---|---|
| UA (1) | UA86441C2 (en) |
| WO (1) | WO2008120070A2 (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010147962A1 (en) | 2009-06-15 | 2010-12-23 | Encore Health, Llc | Choline esters |
| US7914815B2 (en) | 2000-08-16 | 2011-03-29 | Encore Health, Llc | Method for delivery of pharmaceuticals for treating or preventing presbyopia |
| US7935332B2 (en) | 2000-08-16 | 2011-05-03 | Encore Health, Llc | Presbyopia treatment by lens alteration |
| US8147816B2 (en) | 2000-08-16 | 2012-04-03 | Encore Health, Llc | Presbyopia treatment by lens alteration |
| US8647612B2 (en) | 2008-03-05 | 2014-02-11 | Encore Health, Llc | Dithiol compounds, derivatives, and treatment of presbyopia |
| US8697109B2 (en) | 2000-08-16 | 2014-04-15 | Encore Health, Llc | Caged mercaptan and seleno-mercaptan compounds and methods of using them |
| US8795706B2 (en) | 2000-08-16 | 2014-08-05 | Encore Health, Llc | Methods of treating ocular diseases using derivatives of lipoic acid |
| US9044439B2 (en) | 2008-03-05 | 2015-06-02 | Encore Health, Llc | Low dose lipoic and pharmaceutical compositions and methods |
| US9161931B2 (en) | 2008-03-05 | 2015-10-20 | Encore Health, Llc | Dithiol compounds and treatment of presbyopia using said compounds |
| WO2019150341A1 (en) * | 2018-02-05 | 2019-08-08 | Cellixbio Private Limited | Combination of an antimuscarinic or an anticholinergic agent and lipoic acid and uses thereof |
| US11426381B2 (en) | 2014-03-03 | 2022-08-30 | Novartis Ag | Lipoic acid choline ester compositions and methods of use |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1077039A (en) * | 1965-10-21 | 1967-07-26 | Henry Eugene Jean Marie Meunie | A choline derivative and therapeutic compositions containing it |
| WO1999055331A1 (en) * | 1998-04-25 | 1999-11-04 | Skw Trostberg Aktiengesellschaft | Use of alpha lipoic acid to reduce appetite and/or body weight |
-
2007
- 2007-03-30 UA UAA200703481A patent/UA86441C2/en unknown
-
2008
- 2008-03-17 WO PCT/IB2008/000727 patent/WO2008120070A2/en active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1077039A (en) * | 1965-10-21 | 1967-07-26 | Henry Eugene Jean Marie Meunie | A choline derivative and therapeutic compositions containing it |
| WO1999055331A1 (en) * | 1998-04-25 | 1999-11-04 | Skw Trostberg Aktiengesellschaft | Use of alpha lipoic acid to reduce appetite and/or body weight |
Cited By (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9284305B2 (en) | 2000-08-16 | 2016-03-15 | Encore Health, Llc | Methods of treating ocular diseases using derivatives of lipoic acid |
| US7914815B2 (en) | 2000-08-16 | 2011-03-29 | Encore Health, Llc | Method for delivery of pharmaceuticals for treating or preventing presbyopia |
| US7935332B2 (en) | 2000-08-16 | 2011-05-03 | Encore Health, Llc | Presbyopia treatment by lens alteration |
| US8147816B2 (en) | 2000-08-16 | 2012-04-03 | Encore Health, Llc | Presbyopia treatment by lens alteration |
| US10039743B2 (en) | 2000-08-16 | 2018-08-07 | Novartis Ag | Method of treating presbyopia using dithiol compounds and their derivatives |
| US9567314B2 (en) | 2000-08-16 | 2017-02-14 | Encore Health Llc | Dithiol compounds, derivatives, and uses therefor |
| US8795706B2 (en) | 2000-08-16 | 2014-08-05 | Encore Health, Llc | Methods of treating ocular diseases using derivatives of lipoic acid |
| US8697109B2 (en) | 2000-08-16 | 2014-04-15 | Encore Health, Llc | Caged mercaptan and seleno-mercaptan compounds and methods of using them |
| US9204996B2 (en) | 2000-08-16 | 2015-12-08 | Encore Health, Llc | Presbyopia treatment by lens alteration |
| US8747829B2 (en) | 2000-08-16 | 2014-06-10 | Encore Health, Llc | Presbyopia treatment by lens alteration of disulfide bonds and reduction |
| US9517225B2 (en) | 2008-03-05 | 2016-12-13 | Encore Health, Llc | Low dose lipoic acid pharmaceutical compositions and methods |
| US9044439B2 (en) | 2008-03-05 | 2015-06-02 | Encore Health, Llc | Low dose lipoic and pharmaceutical compositions and methods |
| US8647612B2 (en) | 2008-03-05 | 2014-02-11 | Encore Health, Llc | Dithiol compounds, derivatives, and treatment of presbyopia |
| US9161931B2 (en) | 2008-03-05 | 2015-10-20 | Encore Health, Llc | Dithiol compounds and treatment of presbyopia using said compounds |
| US8410162B2 (en) | 2009-06-15 | 2013-04-02 | Encore Health Llc | Choline esters |
| WO2010147962A1 (en) | 2009-06-15 | 2010-12-23 | Encore Health, Llc | Choline esters |
| US9326970B2 (en) | 2009-06-15 | 2016-05-03 | Encore Health Llc | Choline esters |
| EP2821405A1 (en) * | 2009-06-15 | 2015-01-07 | Encore Health, LLC | Choline esters for treating presbyopia and cataract |
| EP2442645A4 (en) * | 2009-06-15 | 2013-03-06 | Encore Health Llc | ESTERS OF CHOLINE |
| EP2442645A1 (en) * | 2009-06-15 | 2012-04-25 | Encore Health, Llc | Choline esters |
| US11426381B2 (en) | 2014-03-03 | 2022-08-30 | Novartis Ag | Lipoic acid choline ester compositions and methods of use |
| WO2019150341A1 (en) * | 2018-02-05 | 2019-08-08 | Cellixbio Private Limited | Combination of an antimuscarinic or an anticholinergic agent and lipoic acid and uses thereof |
| JP2021512876A (en) * | 2018-02-05 | 2021-05-20 | セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ | Combinations of antimuscarinic drugs or anticholinergic drugs and lipoic acid and their use |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008120070A3 (en) | 2008-12-31 |
| UA86441C2 (en) | 2009-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008120070A2 (en) | 2(hydroxyethyl)trimethylammonium thioctate (choline thioctate) displaying hepatoprotective, hypoammoniemic and detoxic action, a method for its production and a pharmaceutical composition based thereon | |
| US5728735A (en) | Pharmaceutical composition containing R-α-lipoic acid or S-α-lipoic acid as active ingredient | |
| AU694125B2 (en) | Anti-stress, anti-impairment and anti-aging drug and process for manufacturing thereof | |
| DE4218572A1 (en) | Synergistic combination of drugs containing as active ingredient alpha-lipoic acid, dihydrolipoic acid, their metabolites as well as the oxidized and reduced enantiomers of alpha-lipoic acid such as R-alpha-lipoic acid or S-alpha-lipoic acid and metabolites of alpha-lipoic acid with vitamins A, B1 -6, B12, C and E | |
| DE102005022276A1 (en) | Derivatives of dihydroxyphenylalanine | |
| WO2007149313A1 (en) | Metformin r-(+) lipoate as an antidiabetic agent for control of diabetic hyperglycemia and diabetic complications | |
| JPS5857397A (en) | Stable s-adenosylmethionine derivative, manufacture and therapeutical composition containing same as active component | |
| DE10151764A1 (en) | Combination of lipoic acid and glutamine in food and pharmaceuticals | |
| WO2007063095A1 (en) | Use of zinc salts of lipoic acid for treating fat metabolism disorders | |
| CN103919778B (en) | A kind of applications of the curcumin analogue S1 of structure containing piperidones in terms of anti-inflammatory drug is prepared | |
| EP4135656A1 (en) | Taxifolin formulation comprising thiamine | |
| US8350077B2 (en) | Amides of creatine, method of their preparation, and remedy possessing a neuroprotective activity | |
| US7202270B2 (en) | Convenient stable non-hygroscopic crystalline solid forms of racemic and chiral LA-plus salts: process for their manufacture and uses | |
| DE4420102A1 (en) | Combination prepns. contg. alpha-liponic acid or its metabolites | |
| CN102803243A (en) | Piperazine Dithioctate And Pharmaceutical Composition Comprising The Same | |
| DE10022856A1 (en) | Treating central nervous system disorders e.g. cognitive deficiency or depression, using combination of lipoic acid and C-1 donor e.g. S-adenosyl-methionine | |
| JPS62190190A (en) | Phosphorylalkanolamide derivatives of l-carnitine and medicinal composition | |
| DE4327462A1 (en) | N-Acetyl-p-aminophenol derivatives for controlling pain | |
| DE60113808T2 (en) | Therapeutic or prophylactic for liver diseases containing a diaminotrifluoroethylpyridine derivative | |
| CN104311622B (en) | A kind of asiatic acid amide derivative | |
| CN103919770B (en) | Application of curcumin analog S5 containing thiapyrone structure in preparation of anti-inflammation drugs | |
| CN102344482A (en) | Betulinol derivant, preparation method and usage | |
| EP2736507B1 (en) | Basic alpha lipoic acid solution and its uses | |
| CN105407884A (en) | Methods for reducing triglyceride, total cholesterol and low density lipoprotein blood levels | |
| DE2116629A1 (en) | 4-thiazolidinecarboxylic acid derivs - with in vivo thiol liberating activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08719373 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 08719373 Country of ref document: EP Kind code of ref document: A2 |